PDL signs humanized AB development deal with Merck & Co
California, USA-based Protein Design Labs, a specialist developer of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer, says that it has entered into an agreement with Merck & Co which grants the latter non-exclusive licenses under PDL's humanization patents for antibodies developed by Merck against two undisclosed targets.
Under the terms of the deal, Merck will make an upfront payment to PDL, in addition to development milestones and royalties on future sales of products resulting from the accord. Further financial details were not provided.
PDL holds various important antibody-related patents and has entered into agreements with numerous companies covering the rights of more than 40 humanized antibodies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze